Tags

Type your tag names separated by a space and hit enter

Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.
Prostate 2008; 68(13):1477-86P

Abstract

BACKGROUND

We investigated whether peptides involved in cellular proliferation and apoptosis, [insulin-like growth factor I (IGFI) and its major binding protein (insulin-like growth factor binding protein 3)], predicted risk of benign prostate hyperplasia (BPH).

METHODS

We conducted a nested-case-control study in the placebo arm of the prostate cancer prevention trial (PCPT). Cases (n = 727) were men with surgical or medical treatment for BPH; two or more IPSS scores >14; or two scores of at least five points over baseline one of which was >or=12. Controls (n = 727) were frequency matched by age to cases, reported no BPH treatment, and no IPSS score >8. Cases and controls remained on the PCPT placebo and were followed closely until their 7-year PCPT anniversary. Baseline serum was analyzed for IGFI and IGFBP3. Unconditional logistic regression and polytomous regression estimated the multivariate-adjusted odds ratio (OR) for BPH risk.

RESULTS

IGFBP3 was inversely and the IGFI:IGFBP3 ratio was positively associated with BPH risk, but findings were statistically significant only for men with severe symptoms (OR = 0.60, 95% CI = 0.40-0.90 for the fifth vs. first quintile of IGFBP3, P-trend = 0.01). Associations did not differ by age (<65 or >or=65 years), and there was a suggestion that the IGFI:IGFBP3 - BPH risk association may be stronger among overweight men.

CONCLUSIONS

A high IGFI:IGFBP3 ratio was associated with increased BPH risk, and high serum IGFBP3 was associated with decreased BPH risk among men with severe symptoms. These results confirm findings from other recent studies.

Authors+Show Affiliations

Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA. mneuhous@fhcrc.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

18618736

Citation

Neuhouser, Marian L., et al. "Insulin-like Growth factor-I, Insulin-like Growth Factor Binding Protein-3 and Risk of Benign Prostate Hyperplasia in the Prostate Cancer Prevention Trial." The Prostate, vol. 68, no. 13, 2008, pp. 1477-86.
Neuhouser ML, Schenk J, Song YJ, et al. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate. 2008;68(13):1477-86.
Neuhouser, M. L., Schenk, J., Song, Y. J., Tangen, C. M., Goodman, P. J., Pollak, M., ... Kristal, A. R. (2008). Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. The Prostate, 68(13), pp. 1477-86. doi:10.1002/pros.20819.
Neuhouser ML, et al. Insulin-like Growth factor-I, Insulin-like Growth Factor Binding Protein-3 and Risk of Benign Prostate Hyperplasia in the Prostate Cancer Prevention Trial. Prostate. 2008 Sep 15;68(13):1477-86. PubMed PMID: 18618736.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. AU - Neuhouser,Marian L, AU - Schenk,Jeannette, AU - Song,Yoon Ju, AU - Tangen,Catherine M, AU - Goodman,Phyllis J, AU - Pollak,Michael, AU - Penson,David F, AU - Thompson,Ian M, AU - Kristal,Alan R, PY - 2008/7/12/pubmed PY - 2008/9/6/medline PY - 2008/7/12/entrez SP - 1477 EP - 86 JF - The Prostate JO - Prostate VL - 68 IS - 13 N2 - BACKGROUND: We investigated whether peptides involved in cellular proliferation and apoptosis, [insulin-like growth factor I (IGFI) and its major binding protein (insulin-like growth factor binding protein 3)], predicted risk of benign prostate hyperplasia (BPH). METHODS: We conducted a nested-case-control study in the placebo arm of the prostate cancer prevention trial (PCPT). Cases (n = 727) were men with surgical or medical treatment for BPH; two or more IPSS scores >14; or two scores of at least five points over baseline one of which was >or=12. Controls (n = 727) were frequency matched by age to cases, reported no BPH treatment, and no IPSS score >8. Cases and controls remained on the PCPT placebo and were followed closely until their 7-year PCPT anniversary. Baseline serum was analyzed for IGFI and IGFBP3. Unconditional logistic regression and polytomous regression estimated the multivariate-adjusted odds ratio (OR) for BPH risk. RESULTS: IGFBP3 was inversely and the IGFI:IGFBP3 ratio was positively associated with BPH risk, but findings were statistically significant only for men with severe symptoms (OR = 0.60, 95% CI = 0.40-0.90 for the fifth vs. first quintile of IGFBP3, P-trend = 0.01). Associations did not differ by age (<65 or >or=65 years), and there was a suggestion that the IGFI:IGFBP3 - BPH risk association may be stronger among overweight men. CONCLUSIONS: A high IGFI:IGFBP3 ratio was associated with increased BPH risk, and high serum IGFBP3 was associated with decreased BPH risk among men with severe symptoms. These results confirm findings from other recent studies. SN - 1097-0045 UR - https://www.unboundmedicine.com/medline/citation/18618736/Insulin_like_growth_factor_I_insulin_like_growth_factor_binding_protein_3_and_risk_of_benign_prostate_hyperplasia_in_the_prostate_cancer_prevention_trial_ L2 - https://doi.org/10.1002/pros.20819 DB - PRIME DP - Unbound Medicine ER -